Study of the Efficacy,Safety and Quality of Life After TOOKAD Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer

Trial Profile

Study of the Efficacy,Safety and Quality of Life After TOOKAD Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Padeliporfin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Steba Biotech
  • Most Recent Events

    • 03 Feb 2016 New trial record
    • 01 Feb 2016 Top-line results published in a Steba Biotech media release.
    • 01 Feb 2016 On the basis of positive results from this trial, Steba Biotech has submitted a marketing authorization application for TOOKAD (padeliporfin) to the Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS), the Mexican health authority. After review, the COFEPRIS has granted the first marketing authorization for TOOKAD for the treatment of low-risk localized prostate cancer patients on November 12, 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top